Perez-Soler R - Search Results

1

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

Cheng H, Zou Y, Ross JS, Wang K, Liu X, Halmos B, Ali SM, Liu H, Verma A, Montagna C, Chachoua A, Goel S, Schwartz EL, Zhu C, Shan J, Yu Y, Gritsman K, Yelensky R, Lipson D, Otto G, Hawryluk M, Stephens PJ, Miller VA, Piperdi B, Perez-Soler R. Cheng H, et al. Cancer Discov. 2015 Dec;5(12):1262-70. doi: 10.1158/2159-8290.CD-14-0971. Epub 2015 Sep 14. Cancer Discov. 2015. PMID: 26370156 Free PMC article.

2

Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients.

Piperdi B, Perez-Soler R. Piperdi B, et al. Drugs. 2012 Jun 19;72 Suppl 1(0 1):11-9. doi: 10.2165/1163018-S0-000000000-00000. Drugs. 2012. PMID: 22712793 Free PMC article. Review.

3

Intratracheally administered 5-azacytidine is effective against orthotopic human lung cancer xenograft models and devoid of important systemic toxicity.

Mahesh S, Saxena A, Qiu X, Perez-Soler R, Zou Y. Mahesh S, et al. Clin Lung Cancer. 2010 Nov 1;11(6):405-11. doi: 10.3816/CLC.2010.n.052. Clin Lung Cancer. 2010. PMID: 21062731 Free PMC article.

4

The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.

Zou Y, Ling YH, Sironi J, Schwartz EL, Perez-Soler R, Piperdi B. Zou Y, et al. J Thorac Oncol. 2013 Jun;8(6):693-702. doi: 10.1097/JTO.0b013e31828c7210. J Thorac Oncol. 2013. PMID: 23575415 Free PMC article.

5

Targeting angiogenesis in squamous non-small cell lung cancer.

Piperdi B, Merla A, Perez-Soler R. Piperdi B, et al. Drugs. 2014 Mar;74(4):403-13. doi: 10.1007/s40265-014-0182-z. Drugs. 2014. PMID: 24578213 Free PMC article. Review.

6

Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment.

Cheng H, Shcherba M, Pendurti G, Liang Y, Piperdi B, Perez-Soler R. Cheng H, et al. Lung Cancer Manag. 2014 Jan 1;3(1):67-75. doi: 10.2217/lmt.13.72. Lung Cancer Manag. 2014. PMID: 25342981 Free PMC article.

7

Emerging drugs for squamous cell lung cancer.

Cheng H, Shcherba M, Kandavelou K, Liang Y, Liu H, Perez-Soler R. Cheng H, et al. Expert Opin Emerg Drugs. 2015 Mar;20(1):149-60. doi: 10.1517/14728214.2015.1001365. Epub 2015 Jan 5. Expert Opin Emerg Drugs. 2015. PMID: 25557559 Review.

8

Emerging treatment for advanced lung cancer with EGFR mutation.

Inal C, Yilmaz E, Piperdi B, Perez-Soler R, Cheng H. Inal C, et al. Expert Opin Emerg Drugs. 2015;20(4):597-612. doi: 10.1517/14728214.2015.1058778. Epub 2015 Jul 8. Expert Opin Emerg Drugs. 2015. PMID: 26153235 Review.

9

Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells.

Cheng H, Zhang Z, Rodriguez-Barrueco R, Borczuk A, Liu H, Yu J, Silva JM, Cheng SK, Perez-Soler R, Halmos B. Cheng H, et al. Oncotarget. 2016 May 17;7(20):28976-88. doi: 10.18632/oncotarget.6721. Oncotarget. 2016. PMID: 26716514 Free PMC article.

10

HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.

Cheng H, Janakiram M, Borczuk A, Lin J, Qiu W, Liu H, Chinai JM, Halmos B, Perez-Soler R, Zang X. Cheng H, et al. Clin Cancer Res. 2017 Feb 1;23(3):825-832. doi: 10.1158/1078-0432.CCR-15-3071. Epub 2016 Aug 23. Clin Cancer Res. 2017. PMID: 27553831 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

206 results

Search Page

Filters